Jeff Cleland
Co-Founder IronFist Therapeutics
Seminars
Thursday 26th February 2026
Licensing & Strategic Alliances: How to Avoid Leaving Value on the Table
11:40 am
- Discussing examples of deal evaluation and success, including details of the process
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and overcome the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for targeted therapies worldwide
Friday 27th February 2026
Aligning Target Biology, Binder Format & Isotope with Tumor Treatment Paradigm
3:30 pm
- Discussing different pharmacokinetic properties of binders, including small molecule, peptide, mAbs and nanoparticles
- Evaluating need, niche, and efficacy when matching target biology to binder format and isotope
- Leveraging imaging to derisk and prove safety to curate a faster path to clinical proof of concept
- How do considerations around isotopes play into deal-making?
